@thebriannalove's Zepbound journey at week 35, reviewed

What did @thebriannalove actually say?

At week 35 on tirzepatide (Zepbound), now at the 15 mg maximum dose, the creator described powerful appetite suppression, saying "the satiety was satiety-ing" to the point where she'd reach 3 p.m. without eating and feel no hunger at all. She was self-aware enough to flag this as a problem, not a flex. She also reported zero side effects on the dose increase, lost two pounds during her period week, and credited heavy lifting, 10K daily steps, and high-protein eating for her results.

She explicitly pushed back on the trend of people bragging about skipping meals on GLP-1s, calling it "not funny or cute." She mentioned prioritizing protein through products like Fairlife Core Power and Premier Protein, and noted she's managing her intake deliberately ahead of her wedding in roughly 120 days.

Does the science back this up?

The appetite suppression she's describing is exactly what the clinical data predicts. Her concern about under-eating is also clinically legitimate, not just personal preference.

Tirzepatide acts on both GIP and GLP-1 receptors, a dual agonist mechanism that produces more pronounced satiety than semaglutide alone. In the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM), participants on 15 mg tirzepatide lost an average of 20.9% of body weight over 72 weeks, with significant reductions in appetite and caloric intake documented throughout. The appetite suppression is real and well-documented.

Her point about side effects decreasing over time also aligns with trial data. Gastrointestinal side effects in SURMOUNT-1 were most common during dose escalation and generally declined with sustained use. By week 35, her body adapting to the medication is a plausible and expected outcome, not luck.

What did they get wrong (or right)?

She got more right than wrong here. Her instinct to prioritize protein while on a GLP-1 is backed by actual evidence. Resistance to muscle loss during GLP-1-induced weight loss is a genuine concern, and protein intake is one of the levers available.

A 2023 analysis by Wilding and colleagues in Diabetes, Obesity and Metabolism noted that lean mass loss during GLP-1 therapy can be substantial if protein intake and resistance training aren't maintained. Her combination of heavy lifting and high protein is not just aesthetic prep for a wedding. It's the right clinical instinct.

Where she's slightly imprecise: saying her body is "just really used to being on the medication" to explain absent side effects is a casual framing of a real pharmacological phenomenon. Tachyphylaxis and receptor adaptation are more complex than habituation, but her conclusion is not wrong. Her note about injecting only in the stomach despite advice to rotate sites is worth flagging. Rotation is recommended to reduce lipohypertrophy risk, and sticking to one site long-term can affect absorption consistency.

What should you actually know?

The most important thing this video accidentally illustrates is how easy it is to under-eat on high-dose tirzepatide, and how little that gets discussed in GLP-1 content. Not eating for most of the day isn't a side effect to brag about. It's a risk factor for muscle loss, nutrient deficiency, and metabolic slowdown.

Research published by Bikou et al. (2023, Nutrients) found that very low caloric intake during GLP-1 therapy, without adequate protein, accelerates lean mass reduction disproportionately. If you're on a GLP-1 and not actively tracking protein, you may be losing muscle alongside fat, which undermines long-term metabolic health and weight maintenance.

Injection site rotation also matters more than she acknowledged. The FDA prescribing information for tirzepatide specifically recommends rotating injection sites across the abdomen, thigh, and upper arm to reduce local tissue changes. It's a small thing, but after 35 weeks in one location, it's worth reconsidering.

• Tirzepatide's 15 mg dose produces the strongest appetite suppression in the approved range. Feeling full to the point of forgetting to eat is a documented drug effect, not a personal achievement.
• Skipping meals on a GLP-1 is not the same as healthy caloric restriction. Protein and micronutrient targets still need to be hit.
• Resistance training during GLP-1 therapy is not optional if preserving muscle mass matters to you. The evidence supports it strongly.
• Side effect reduction after prolonged use at a stable dose is expected and documented in clinical trials.
• Injecting exclusively in one site for months is a real concern for absorption and tissue health. Rotation isn't just a suggestion.